Search research articles
Contact Us
Filters
Showing results (61-70 of 265) with videos related to
Page
of 27
Sort By:
The American Journal of Managed Care
|
October 23, 2010
Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System
Walid F Gellad, Chester B Good, John C Lowe, et al.
JAMA
|
February 12, 2016
Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review
Jonathan S Lee, Daniel L Giesler, Walid F Gellad, et al.
JAMA
|
March 4, 2020
Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
Inmaculada Hernandez, Alvaro San-Juan-Rodriguez, Chester B Good, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
September 17, 2019
Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation
Inmaculada Hernandez, Meiqi He, Maria M Brooks, et al.
The Lancet. Global Health
|
June 17, 2021
Socially optimal pandemic drug dosing
Garth W Strohbehn, William F Parker, Pankti D Reid, et al.
Pharmacoepidemiology and Drug Safety
|
October 11, 2017
The myths of medication adherence
Walid F Gellad, Carolyn T Thorpe, John F Steiner, et al.
JAMA Network Open
|
December 14, 2019
Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
Alvaro San-Juan-Rodriguez, Walid F Gellad, Chester B Good, et al.
Journal of General Internal Medicine
|
May 16, 2007
Angiotensin receptor blockers on the formularies of Medicare drug plans
Walid F Gellad, Haiden A Huskamp, Kathryn A Phillips, et al.
Journal of General Internal Medicine
|
June 27, 2008
What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings
Walid F Gellad, Sebastian Schneeweiss, Phyllis Brawarsky, et al.
JAMA Network Open
|
October 15, 2020
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
Jing Luo, Robert Feldman, Scott D Rothenberger, et al.
Page
of 27
Search research articles
Search
Showing results (61-70 of 265) with videos related to
Sort By:
Page
of 27
The American Journal of Managed Care
|
October 23, 2010
Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System
Walid F Gellad, Chester B Good, John C Lowe, et al.
JAMA
|
February 12, 2016
Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review
Jonathan S Lee, Daniel L Giesler, Walid F Gellad, et al.
JAMA
|
March 4, 2020
Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
Inmaculada Hernandez, Alvaro San-Juan-Rodriguez, Chester B Good, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
September 17, 2019
Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation
Inmaculada Hernandez, Meiqi He, Maria M Brooks, et al.
The Lancet. Global Health
|
June 17, 2021
Socially optimal pandemic drug dosing
Garth W Strohbehn, William F Parker, Pankti D Reid, et al.
Pharmacoepidemiology and Drug Safety
|
October 11, 2017
The myths of medication adherence
Walid F Gellad, Carolyn T Thorpe, John F Steiner, et al.
JAMA Network Open
|
December 14, 2019
Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
Alvaro San-Juan-Rodriguez, Walid F Gellad, Chester B Good, et al.
Journal of General Internal Medicine
|
May 16, 2007
Angiotensin receptor blockers on the formularies of Medicare drug plans
Walid F Gellad, Haiden A Huskamp, Kathryn A Phillips, et al.
Journal of General Internal Medicine
|
June 27, 2008
What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings
Walid F Gellad, Sebastian Schneeweiss, Phyllis Brawarsky, et al.
JAMA Network Open
|
October 15, 2020
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
Jing Luo, Robert Feldman, Scott D Rothenberger, et al.
Page
of 27